Aims: The study aimed at developing and characterizing Nanostructured Lipid Carriers (NLC) of Quetiapine Fumarate (QF) by Design of Experiment (DoE) for the enhancement of bioavailability.
Background: QF, an anti-psychotic drug, has an oral bioavailability of 9% due to hepatic first- pass metabolism necessitating the use of high doses. Its side effects are dose -related and enhancement in bioavailability would result in minimization of side effects.
Objective: The objective of the study was the enhancement of bioavailability of the NLC of QF by preferential lymphatic uptake.
Methods: Hot emulsification-ultrasonication was the method of formulation using PrecirolATO5 and Oleic acid as solid and liquid lipids respectively. Poloxamer188 and Phospholipon90G were used as surfactant and stabilizer respectively. Solid:liquid lipid ratio and Phospholipon90G amount were independent variables and percent Entrapment Efficiency (%EE), Particle Size (PS) dependent variables during optimization by Central Composite Design.
Results: The optimized formulation showed a %EE of 77.21%, PS of 140.2 nm and surface charge of - 19.9mV. Higuchi kinetic model was followed during the in-vitro release. TEM revealed spherical, smooth nanoparticles. A pharmacokinetic study in rats showed AUC0-∞ of QF-NLC to be 3.93 times that of QF in suspension, suggesting significant enhancement in bioavailability. An increase in AUC0-∞ in cycloheximide untreated rats’ group of QF-NLC by 2.43 times as compared to cycloheximide treated group, confirmed lymphatic absorption of QF- NLC.
Conclusion: The results validated DoE as an appropriate tool for developing QF loaded NLC and proved NLC to be a promising delivery system for the enhancement of oral bioavailability of QF.
[http://dx.doi.org/10.2165/00003088-200140070-00003] [PMID: 11510628]
[http://dx.doi.org/10.3797/scipharm.1202-12] [PMID: 23008819]
[http://dx.doi.org/10.1002/jps.22711] [PMID: 22020815]
[http://dx.doi.org/10.1016/j.ijpharm.2016.12.044] [PMID: 28025072]
[http://dx.doi.org/10.1080/21691401.2018.1465068] [PMID: 29688077]
[http://dx.doi.org/10.1080/03639045.2017.1318897] [PMID: 28402145]
[http://dx.doi.org/10.1208/s12249-014-0175-y] [PMID: 25035071]
[http://dx.doi.org/10.2147/IJN.S131893] [PMID: 28458544]
[http://dx.doi.org/10.1007/s13197-017-2937-5] [PMID: 29358821]